<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01285999</url>
  </required_header>
  <id_info>
    <org_study_id>S2227</org_study_id>
    <nct_id>NCT01285999</nct_id>
  </id_info>
  <brief_title>A Prospective, Randomized, Multicenter Trial to Assess an Everolimus-Eluting Coronary Stent System (PROMUS™ Element™) for the Treatment of a Single De Novo Coronary Artery Lesion</brief_title>
  <acronym>PLATINUM China</acronym>
  <official_title>PLATINUM China: A Prospective, Randomized, Multicenter Trial to Assess an Everolimus-Eluting Coronary Stent System (PROMUS™ Element™) for the Treatment of a Single De Novo Coronary Artery Lesion</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boston Scientific Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boston Scientific Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and effectiveness of the PROMUS™ Element™
      Everolimus-Eluting Coronary Stent System for the treatment of subjects in China with a single
      de novo atherosclerotic coronary artery lesion.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>January 2011</start_date>
  <completion_date type="Anticipated">April 2014</completion_date>
  <primary_completion_date type="Anticipated">March 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>9 Month in-stent late loss</measure>
    <time_frame>9 Months</time_frame>
    <description>The primary endpoint is in-stent late loss measured by quantitative coronary angiography (QCA) at 9 months post-index procedure.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Target vessel failure (TVF) rate</measure>
    <time_frame>In hospital and at 30 days, 6 months, 9 months, 12 months, and 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target lesion revascularization (TLR) rate</measure>
    <time_frame>In hospital and at 30 days, 6 months, 9 months, 12 months, and 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target vessel revascularization (TVR) rate</measure>
    <time_frame>In hospital and at 30 days, 6 months, 9 months, 12 months, and 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target lesion failure (TLF) rate</measure>
    <time_frame>In hospital and at 30 days, 6 months, 9 months, 12 months, and 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major adverse cardiac event (MACE) rate</measure>
    <time_frame>In hospital and at 30 days, 6 months, 9 months, 12 months, and 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial Infarction (MI)(Q-wave and non-Q-wave) rate</measure>
    <time_frame>In hospital and at 30 days, 6 months, 9 months, 12 months, and 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac death rate</measure>
    <time_frame>In hospital and at 30 days, 6 months, 9 months, 12 months, and 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-cardiac death rate</measure>
    <time_frame>In hospital and at 30 days, 6 months, 9 months, 12 months, and 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All death rate</measure>
    <time_frame>In hospital and at 30 days, 6 months, 9 months, 12 months, and 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac death or MI rate</measure>
    <time_frame>In hospital and at 30 days, 6 months, 9 months, 12 months, and 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent thrombosis rate (definite or probable by Academic Research Consortium [ARC] definitions)</measure>
    <time_frame>In hospital and at 30 days, 6 months, 9 months, 12 months, and 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Angiographic endpoints: In-stent and in-segment percent diameter stenosis (%DS), In-segment late loss , In-stent and in-segment binary restenosis rate, In-stent and in-segment minimum lumen diameter (MLD, Stent fracture rate</measure>
    <time_frame>9 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Periprocedural endpoints: Technical success rate, Clinical procedural success rate, MLD (QCA), Acute gain (QCA)</measure>
    <time_frame>In hospital</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Atherosclerosis</condition>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>PROMUS Element</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PROMUS Element Everolimus-Eluting Coronary Stent System (PROMUS Element)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TAXUS Liberté</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>TAXUS Liberté Paclitaxel-Eluting Coronary Stent System (TAXUS Liberté)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>PROMUS Element Coronary Stent System</intervention_name>
    <description>Everolimus-eluting Coronary Stent</description>
    <arm_group_label>PROMUS Element</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>TAXUS Liberté Coronary Stent System</intervention_name>
    <description>Paclitaxel-eluting Coronary Stent</description>
    <arm_group_label>TAXUS Liberté</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Clinical Inclusion Criteria:

          -  Subject must be age 18 - 75 years

          -  Subject (or legal guardian) understands the trial requirements and the treatment
             procedures and provides written informed consent before any trial- specific tests or
             procedures are performed

          -  Subject is eligible for percutaneous coronary intervention (PCI)

          -  Subject has symptomatic coronary artery disease or documented silent ischemia

          -  Subject is an acceptable candidate for coronary artery bypass grafting (CABG)

          -  Subject has a left ventricular ejection fraction (LVEF) ≥30% as measured within 60
             days prior to enrollment

          -  Subject is willing to comply with all protocol-required follow-up evaluations

        Angiographic Inclusion Criteria:

          -  Target lesion must be a de novo lesion located in a native coronary artery with a
             visually estimated reference vessel diameter (RVD) ≥2.50 mm and ≤ 4.00 mm.

          -  Target lesion length must measure &lt;38 mm (by visual estimate)

          -  Target lesion must have visually estimated stenosis ≥50% and &lt;100% with Thrombolysis
             in Myocardial Infarction (TIMI) flow &gt;1.

          -  Target lesion must be successfully pre-dilated.

        Exclusion Criteria:

          -  Subject has clinical symptoms and/or electrocardiogram (ECG) changes consistent with
             acute MI

          -  Subject with unstable angina or recent MI (within 1 week) must have creatine kinase
             (CK)/ creatine kinase-myoglobin band(CK-MB) or troponin documented prior to the
             procedure and are excluded if any of the following criteria are met at the time of the
             index procedure:

               -  of CK MB &gt;2× upper limit of normal (ULN), the subject is excluded regardless of
                  the CK Total.

               -  If CK Total &gt;2× ULN, either CK-MB or troponin must be drawn and the subject is
                  excluded if either CK-MB or troponin is abnormal.

               -  If neither CK Total or CK MB is drawn but troponin is, the subject is excluded if
                  troponin &gt;1× ULN and the subject has at least one of the following:

                    -  Subject has ischemic symptoms and ECG changes indicative of ongoing ischemia
                       (e.g., &gt;1 mm stent thrombosis (ST) segment elevation or depression in
                       consecutive leads or new left bundle branch block [LBBB])

                    -  Development of pathological Q waves in the ECG or;

                    -  Imaging evidence of new loss of viable myocardium or new regional wall
                       motion abnormality Note: Subjects who do not have recent MI or unstable
                       angina must still have CK/CK-MB or troponin drawn prior to the index
                       procedure. However, the results for these subjects do not need to be
                       available prior to the index procedure and there are no exclusion criteria
                       based on these laboratory studies.

          -  Subject has received an organ transplant or is on a waiting list for an organ
             transplant

          -  Subject is receiving or scheduled to receive chemotherapy within 30 days before or
             after the index procedure

          -  Subject is receiving oral or intravenous immunosuppressive therapy (Note: use of
             inhaled steroids does not exclude subjects) or has known life- limiting
             immunosuppressive or autoimmune disease (e.g., human immunodeficiency virus, systemic
             lupus erythematosus; Note: this does not include diabetes mellitus)

          -  Subject is receiving chronic (≥72 hours) anticoagulation therapy (e.g., heparin,
             coumadin) for indications other than acute coronary syndrome

          -  Subject has a platelet count &lt;100,000 cells/mm3 or &gt;700,000 cells/mm3

          -  Subject has a white blood cell (WBC) count &lt;3,000 cells/mm3

          -  Subject has documented or suspected liver disease, including laboratory evidence of
             hepatitis

          -  Subject is on dialysis or has serum creatinine level &gt;2.0 mg/dL

          -  Subject has active peptic ulcer disease, an active gastrointestinal (GI) bleed, other
             bleeding diathesis or coagulopathy or will refuse transfusions

          -  Subject has had a cerebrovascular accident (CVA) or transient ischemic attack (TIA)
             within the past 6 months, or has any permanent neurologic defect that may cause
             non-compliance with the protocol

          -  Target vessel (including side branches) has been treated with any type of PCI (e.g.,
             balloon angioplasty, stent, cutting balloon, atherectomy) within 12 months prior to
             the index procedure

          -  Target vessel has been treated within 10 mm proximal or distal to the target lesion
             (by visual estimate) with any type of PCI (e.g., balloon angioplasty, stent, cutting
             balloon, atherectomy) at any time prior to the index procedure

          -  Non-target vessel has been treated with any type of PCI (e.g., balloon angioplasty,
             stent, cutting balloon, atherectomy) within 24 hours prior to the index procedure

          -  Planned or actual target vessel treatment with an unapproved device, directional or
             rotational coronary atherectomy, laser, cutting balloon, or transluminal extraction
             catheter immediately prior to stent placement

          -  Planned PCI or CABG after the index procedure

          -  Subject previously treated at any time with coronary intravascular brachytherapy

          -  Subject has known allergy to the study stent system or protocol-required concomitant
             medications (e.g., everolimus, paclitaxel or structurally related compounds;
             fluoropolymers; thienopyridines or aspirin; contrast; acrylic; stainless steel;
             platinum; chromium; nickel; iron; tungsten) that cannot be adequately premedicated

          -  Subject has any other serious medical illness (e.g., cancer, congestive heart failure)
             that may reduce life expectancy to less than 12 months

          -  Subject has current problems with substance abuse (e.g., alcohol, cocaine, heroin,
             etc.)

          -  Subject has a planned procedure that may cause non-compliance with the protocol or
             confound data interpretation

          -  Subject is participating in another investigational drug or device clinical trial that
             has not reached its primary endpoint or intends to participate in another
             investigational drug or device clinical trial within 12 months after the index
             procedure

          -  Subject with known intention to procreate within 12 month after the index procedure
             (Women of child-bearing potential who are sexually active must agree to use a reliable
             method of contraception from the time of screening through 12 month after the index
             procedure.)

          -  Subject is a woman who is pregnant or nursing (A pregnancy test must be performed
             within 7 days prior to the index procedure in women of child- bearing potential.)

          -  Subject has more than 1 lesion that requires treatment during the index procedure

        Angiographic Exclusion Criteria:

          -  Target lesion meets any of the following criteria:

               -  Left main location

               -  Located within 5 mm of the origin of the left anterior descending (LAD) coronary
                  artery or left circumflex (LCX) coronary artery or Right Coronary Artery (RCA) by
                  visual estimate

               -  Located within a saphenous vein graft or an arterial graft

               -  Will be accessed via a saphenous vein graft or an arterial graft

               -  Involves a side branch ≥2.0 mm in diameter by visual estimate

               -  Involves a side branch &lt;2.0 mm in diameter by visual estimate which requires
                  treatment

               -  TIMI flow 0 (total occlusion) or TIMI flow 1 prior to guide wire crossing

               -  Excessive tortuosity proximal to or within the lesion

               -  Excessive angulation proximal to or within the lesion

               -  Target lesion and/or target vessel proximal to the target lesion ismoderately to
                  severely calcified by visual estimate

               -  Restenotic from previous intervention

               -  Thrombus, or possible thrombus, present in the target vessel

               -  Target lesion cannot be covered by a single study stent (unplanned bailout
                  stenting is allowed)

          -  Subject has unprotected left main coronary artery disease (&gt;50% diameter stenosis)

          -  Subject has protected left main coronary artery disease (&gt;50% diameter stenosis in the
             LMCA with bypass graft[s] to the left coronary artery) and a target lesion in the LAD
             or LCX

          -  Subject has an additional clinically significant lesion(s) for which an intervention
             within 12 months after the index procedure may be required
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter Maurer</last_name>
    <role>Study Director</role>
    <affiliation>Boston Scientific Corporation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cardiovascular Institute and Fu Wai Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peking Union Medical College Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peking University First Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Chinese People's Liberation Army General Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Huaxi Hospital of Sichuan University</name>
      <address>
        <city>Chengdu</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Daqing General Oil Field Hospital</name>
      <address>
        <city>Daqing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Guangdong Cardiovascular Institute of Guangdong Provincial Hospital</name>
      <address>
        <city>Guangzhou</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Guangdong Nanfang Hospital</name>
      <address>
        <city>Guangzhou</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The 2nd Affiliated Hospital of Harbin Medical University</name>
      <address>
        <city>Harbin</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nanjing First Hospital</name>
      <address>
        <city>Nanjing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shanghai 6th People's Hospital, Jiaotong University</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shanghai Chest Hospital of Jiaotong University</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>General Hospital of SY Military Institute</name>
      <address>
        <city>Shen Yang</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>TEDA International Cardiovascular Hospital</name>
      <address>
        <city>Tianjin</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Xijing Hospital, Fourth Military Medical University</name>
      <address>
        <city>Xi'an</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 25, 2011</study_first_submitted>
  <study_first_submitted_qc>January 28, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 31, 2011</study_first_posted>
  <last_update_submitted>January 30, 2013</last_update_submitted>
  <last_update_submitted_qc>January 30, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 31, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Atherosclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>November 6, 2014</submitted>
    <returned>November 13, 2014</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

